Meanwhile, other patients without opportunities for target therapy are still fighting for their lives, especially individuals with KRAS mutations who were previously thought to be insensitive to chemotherapy with poor prognosis, accounting for 5%–10% and 25%–50% of NSCLC cases in the Chinese population and 25%–50% in Western countries, respectively.4, 5, 6, 7, 8. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.